ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2016
Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis.Journal of cancer survivorship : research and practice · 2026Pooled it
- Analytical Validation of MyProstateScore 2.0-Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay.Diagnostics (Basel, Switzerland) · 2026Article
- Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer.Journal of cancer research and clinical oncology · 2026Article
- Generating 2.5D pathology for enhanced viewing and AI diagnosis.Journal of pathology informatics · 2025Article
- Recommendations from Imaging, Oncology, and Radiology Organizations to Guide Management in Prostate Cancer: Summary of Current Recommendations.Radiology. Imaging cancer · 2025Review
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.International journal of molecular sciences · 2025Review
- Digital Volumetric Biopsy Cores Improve Gleason Grading of Prostate Cancer Using Deep Learning.ArXiv · 2024Article
- Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.The Prostate · 2023Review
- A multi-resolution model for histopathology image classification and localization with multiple instance learning.Computers in biology and medicine · 2021Article
- PTEN status assessment in the Johns Hopkins active surveillance cohort.Prostate cancer and prostatic diseases · 2019Article
- The Quality of Life among Men Receiving Active Surveillance for Prostate Cancer: An Integrative Review.Healthcare (Basel, Switzerland) · 2019Review
- Green tea extract for prevention of prostate cancer progression in patients on active surveillance.Oncotarget · 2018Review
- Landmarks in prostate cancer.Nature reviews. Urology · 2018Review
- Biomarkers in active surveillance.Translational andrology and urology · 2018Review
- Article
- [Multiparametric MRI of the prostate : Important radiological findings for urologists].Der Radiologe · 2017Review
- Current Management Strategy for Active Surveillance in Prostate Cancer.Current oncology reports · 2017Review
- Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.Reviews in urology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Active surveillance (AS) has emerged as a standard management option for men with very low-risk and low-risk prostate cancer, and contemporary data indicate that use of AS is increasing in the United States and abroad. In the favorable-risk population, reports from multiple prospective cohorts indicate a less than 1% likelihood of metastatic disease and prostate cancer-specific mortality over intermediate-term follow-up (median 5-6 years). Higher-risk men participating in AS appear to be at increased risk of adverse outcomes, but these populations have not been adequately studied to this point. Although monitoring on AS largely relies on serial prostate biopsy, a procedure associated with considerable morbidity, there is a need for improved diagnostic tools for patient selection and monitoring. Revisions from the 2014 International Society of Urologic Pathology consensus conference have yielded a more intuitive reporting system and detailed reporting of low-intermediate grade tumors, which should facilitate the practice of AS. Meanwhile, emerging modalities such as multiparametric magnetic resonance imaging and tissue-based molecular testing have shown prognostic value in some populations. At this time, however, these instruments have not been sufficiently studied to consider their routine, standardized use in the AS setting. Future studies should seek to identify those platforms most informative in the AS population and propose a strategy by which promising diagnostic tools can be safely and efficiently incorporated into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.